Oncomatryx - About the company
Oncomatryx is a series D company based in Derio (Spain), founded in 2009 by Laureano Simon. It operates as a Developer of antibody-drug conjugates targeting the tumor microenvironment. Oncomatryx has raised $119M in funding from BBK and Ekarpen. The company has 3297 active competitors, including 1129 funded and 777 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio.
Company Details
Developer of antibody-drug conjugates targeting the tumor microenvironment. It develops novel therapies focused on modulating the tumor's microenvironment to overcome resistance to conventional cancer treatments. The company conducts clinical trials and is committed to bringing innovative solutions to cancer patients. Research efforts concentrate on understanding and targeting the tumor stroma, a new avenue for treating metastatic solid tumors. This approach involves orchestrated combinations of precision drugs targeting both the tumor and its surrounding microenvironment.
- Website
- oncomatryx.com
- Social
- Email ID
- *****@oncomatryx.com
- Phone Number
- +34 **********
Key Metrics
Founded Year
2009
Location
Derio, Spain
Stage
Series D
Total Funding
$119M in 4 rounds
Latest Funding Round
Ranked
413th among 3297 active competitors
Investment & Acquisitions
Similar Companies
Sign up to download Oncomatryx's company profile
Oncomatryx's funding and investors
Oncomatryx has raised a total funding of $119M over 4 rounds. Its first funding round was on Nov 01, 2019. Its latest funding round was a Series D round on Mar 30, 2026 for $*****. 4 investors participated in its latest round. Oncomatryx has 5 institutional investors.
Here is the list of recent funding rounds of Oncomatryx:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Mar 30, 2026 | 8182371 | Series D | 1721399 | 3493883 | 3907228 | 1412767 |
Jan 27, 2025 | 9131672 | Series C | 8675111 | 9124614 | 9440251 | |
Apr 19, 2022 | 5841092 | Series B | 6082134 | 5872173 | 5671726 | 7847106 |
Access funding benchmarks and valuations. Sign up today!View details of Oncomatryx's funding rounds and investors
Oncomatryx's founders and board of directors
Founder? Claim ProfileThe founders of Oncomatryx is Laureano Simon.
Here are the details of Oncomatryx's key team members:
- Laureano Simon: Founder & CEO of Oncomatryx. Contact Info: 1 email address
View details of Oncomatryx's Founder profiles and Board Members
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Oncomatryx's Competitors and alternates
Top competitors of Oncomatryx include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of Oncomatryx, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 75/100 | |
3rd | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 72/100 | |
5th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
6th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
7th | Karyopharm 2008, Newton (United States), Public | Biopharmaceutical company focused on developing and commercializing innovative cancer therapies | $98.4M | 71/100 | |
8th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 71/100 | |
9th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
10th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
413th | Oncomatryx 2009, Derio (Spain), Series D | Developer of antibody-drug conjugates targeting the tumor microenvironment | $119M | 55/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Oncomatryx's competitors? Click here to see the top ones
Oncomatryx's Investments and acquisitions
Oncomatryx has acquired Tube Pharma. Oncomatryx has not made any investments as of now.News related to Oncomatryx
Filter this listMedia has covered Oncomatryx for 1 event in last 1 year.
•
ONCOMATRYX Raises $67 Million to Foster Its Quantum ADCs Clinical DevelopmentThe Joplin Globe•Mar 30, 2026•Oncomatryx, Kutxa Fundazioa, Ekarpen
•
•
•
•
TFS HealthScience Expands Collaboration with Oncomatryx for Pancreatic Cancer TrialPR Newswire•May 06, 2025•TFS, Oncomatryx
•
•
ONCOMATRYX Raises €25 Million to Foster OMTX705 Clinical TrialsBusiness Wire•Jan 27, 2025•Oncomatryx, CDTI
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Oncomatryx
Explore our recently published companies
- Uvtcpl - India based, Unfunded company
- Diamondexch99 - Unfunded company
- Krishna's Herbal & Ayurveda - Jodhpur based, 2007 founded, Funding Raised company
- Dash - Atlanta based, 2025 founded, Unfunded company
- Bregma Science LLP - Bengaluru based, Unfunded company
- Nordible - Mumbai based, 2015 founded, Unfunded company
